E-Poster Abstracts

EP0858 Clinicopathologic significance of fibrosis patterns in HCC and   cholangiocarcinoma 

EP0349 Gender-based difference in patterns of Metabolic Dysfunction-Associated Steatotic Liver disease associated hepatocellular carcinoma induced by diethylnitrosamine combined western diet in mice.

EP0377 Different fibrosis parts correlated with different types of vascular proliferation in two independent MASLD cohorts

EP1035  Impact of liver biopsy size on fibrosis evaluation using second harmonic generation/two-photon excitation fluorescence microscopy 

Oral Presentations

ORAL SESSION 12: Metabolic Dysfunction-Associated Fatty Liver Disease
(MAFLD) and Toxicity

Room 403, Level 4
15:30-16:30 | 28 Mar

16:10-16:20 OP0077 ASSESSMENT OF FIBROSIS CHANGE RATES IN MASH DRUG-TRIAL PLACEBO-ARM VIA PATHOLOGIST READINGS AND qFIBROSIS VALUES 

16:20-16:30 OP0078 AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study 

ORAL SESSION 64: New Techonology

Room 405, Level 4
10:00-11:00 l 30 Mar

10:00-10:10 OP0383 Stain-free digital pathology imaging reveals microarchitectural insights into disease activity and scar evolution to enable outcome prediction in metabolic dysfunction-associated steatotic liver disease 

ORAL SESSION 33:Liver Fibrogenesis and Cirrhosis
Room 405, Level 4
11:00-12:00 | 29 Mar

11:00-11:10 OP0199 EVALUATING IMPACT OF WEIGHT CHANGES ON HISTOLOGICAL PATTERNS OF LIVER FIBROSIS IN MASH: IMPLICATIONS FOR SPATIAL INTERROGATION

ORAL SESSION 37: Metabolic Dysfunction-Associated Fatty Liver Disease
(MAFLD) and Toxicity

Room 403, Level 4
13:30-14:30 | 29 Mar

14:00-14:10 OP0226 Dietary change affects steatosis patterns in hepatocellular carcinoma with Metabolic Dysfunction-Associated Steatotic Liver Disease analyzing by SHG/TPE microscopy imaging combined with scRNA-seq 

Poster Abstract

PP0545  AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 study